Downregulation of miRNA-146a-5p promotes malignant transformation of mesenchymal stromal/stem cells by glioma stem-like cells. 2020

Xingliang Dai, and Yunfei Wang, and Xuchen Dong, and Minfeng Sheng, and Haiyang Wang, and Jia Shi, and Yujing Sheng, and Liang Liu, and Qianqian Jiang, and Yanming Chen, and Bingshan Wu, and Xuejun Yang, and Hongwei Cheng, and Chunsheng Kang, and Jun Dong
Brain Tumor Lab, Department of Neurosurgery, The Second Affiliated Hospital of Soochow University, Suzhou 215004, China.

Mesenchymal stromal/stem cells (MSCs) are promising carriers in cell-based therapies against central nervous system diseases, and have been evaluated in various clinical trials in recent years. However, bone marrow-derived MSCs (BMSCs) are reportedly involved in tumorigenesis initiated by glioma stem-like cells (GSCs). We therefore established three different orthotopic models of GSC-MSC interactions in vivo using dual-color fluorescence tracing. Cell sorting and micropipetting techniques were used to obtain highly proliferative MSC monoclones from each model, and these cells were identified as transformed MSC lines 1, 2 and 3. Nineteen miRNAs were upregulated and 24 miRNAs were downregulated in all three transformed MSC lines compared to normal BMSCs. Reduced miR-146a-5p expression in the transformed MSCs was associated with their proliferation, malignant transformation and overexpression of heterogeneous nuclear ribonucleoprotein D. These findings suggest that downregulation of miR-146a-5p leads to overexpression of its target gene, heterogeneous nuclear ribonucleoprotein D, thereby promoting malignant transformation of MSCs during interactions with GSCs. Given the risk that MSCs will undergo malignant transformation in the glioma microenvironment, targeted glioma therapies employing MSCs as therapeutic carriers should be considered cautiously.

UI MeSH Term Description Entries
D008297 Male Males
D002471 Cell Transformation, Neoplastic Cell changes manifested by escape from control mechanisms, increased growth potential, alterations in the cell surface, karyotypic abnormalities, morphological and biochemical deviations from the norm, and other attributes conferring the ability to invade, metastasize, and kill. Neoplastic Transformation, Cell,Neoplastic Cell Transformation,Transformation, Neoplastic Cell,Tumorigenic Transformation,Cell Neoplastic Transformation,Cell Neoplastic Transformations,Cell Transformations, Neoplastic,Neoplastic Cell Transformations,Neoplastic Transformations, Cell,Transformation, Cell Neoplastic,Transformation, Tumorigenic,Transformations, Cell Neoplastic,Transformations, Neoplastic Cell,Transformations, Tumorigenic,Tumorigenic Transformations
D005260 Female Females
D005910 Glioma Benign and malignant central nervous system neoplasms derived from glial cells (i.e., astrocytes, oligodendrocytes, and ependymocytes). Astrocytes may give rise to astrocytomas (ASTROCYTOMA) or glioblastoma multiforme (see GLIOBLASTOMA). Oligodendrocytes give rise to oligodendrogliomas (OLIGODENDROGLIOMA) and ependymocytes may undergo transformation to become EPENDYMOMA; CHOROID PLEXUS NEOPLASMS; or colloid cysts of the third ventricle. (From Escourolle et al., Manual of Basic Neuropathology, 2nd ed, p21) Glial Cell Tumors,Malignant Glioma,Mixed Glioma,Glial Cell Tumor,Glioma, Malignant,Glioma, Mixed,Gliomas,Gliomas, Malignant,Gliomas, Mixed,Malignant Gliomas,Mixed Gliomas,Tumor, Glial Cell,Tumors, Glial Cell
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D014408 Biomarkers, Tumor Molecular products metabolized and secreted by neoplastic tissue and characterized biochemically in cells or BODY FLUIDS. They are indicators of tumor stage and grade as well as useful for monitoring responses to treatment and predicting recurrence. Many chemical groups are represented including HORMONES; ANTIGENS; amino and NUCLEIC ACIDS; ENZYMES; POLYAMINES; and specific CELL MEMBRANE PROTEINS and LIPIDS. Biochemical Tumor Marker,Cancer Biomarker,Carcinogen Markers,Markers, Tumor,Metabolite Markers, Neoplasm,Tumor Biomarker,Tumor Marker,Tumor Markers, Biochemical,Tumor Markers, Biological,Biochemical Tumor Markers,Biological Tumor Marker,Biological Tumor Markers,Biomarkers, Cancer,Marker, Biochemical Tumor,Marker, Biologic Tumor,Marker, Biological Tumor,Marker, Neoplasm Metabolite,Marker, Tumor Metabolite,Markers, Biochemical Tumor,Markers, Biological Tumor,Markers, Neoplasm Metabolite,Markers, Tumor Metabolite,Metabolite Markers, Tumor,Neoplasm Metabolite Markers,Tumor Markers, Biologic,Tumor Metabolite Marker,Biologic Tumor Marker,Biologic Tumor Markers,Biomarker, Cancer,Biomarker, Tumor,Cancer Biomarkers,Marker, Tumor,Markers, Biologic Tumor,Markers, Carcinogen,Metabolite Marker, Neoplasm,Metabolite Marker, Tumor,Neoplasm Metabolite Marker,Tumor Biomarkers,Tumor Marker, Biochemical,Tumor Marker, Biologic,Tumor Marker, Biological,Tumor Markers,Tumor Metabolite Markers
D015536 Down-Regulation A negative regulatory effect on physiological processes at the molecular, cellular, or systemic level. At the molecular level, the major regulatory sites include membrane receptors, genes (GENE EXPRESSION REGULATION), mRNAs (RNA, MESSENGER), and proteins. Receptor Down-Regulation,Down-Regulation (Physiology),Downregulation,Down Regulation,Down-Regulation, Receptor
D051379 Mice The common name for the genus Mus. Mice, House,Mus,Mus musculus,Mice, Laboratory,Mouse,Mouse, House,Mouse, Laboratory,Mouse, Swiss,Mus domesticus,Mus musculus domesticus,Swiss Mice,House Mice,House Mouse,Laboratory Mice,Laboratory Mouse,Mice, Swiss,Swiss Mouse,domesticus, Mus musculus

Related Publications

Xingliang Dai, and Yunfei Wang, and Xuchen Dong, and Minfeng Sheng, and Haiyang Wang, and Jia Shi, and Yujing Sheng, and Liang Liu, and Qianqian Jiang, and Yanming Chen, and Bingshan Wu, and Xuejun Yang, and Hongwei Cheng, and Chunsheng Kang, and Jun Dong
November 2017, Oncotarget,
Xingliang Dai, and Yunfei Wang, and Xuchen Dong, and Minfeng Sheng, and Haiyang Wang, and Jia Shi, and Yujing Sheng, and Liang Liu, and Qianqian Jiang, and Yanming Chen, and Bingshan Wu, and Xuejun Yang, and Hongwei Cheng, and Chunsheng Kang, and Jun Dong
August 2022, Cell death & disease,
Xingliang Dai, and Yunfei Wang, and Xuchen Dong, and Minfeng Sheng, and Haiyang Wang, and Jia Shi, and Yujing Sheng, and Liang Liu, and Qianqian Jiang, and Yanming Chen, and Bingshan Wu, and Xuejun Yang, and Hongwei Cheng, and Chunsheng Kang, and Jun Dong
September 2023, CNS neuroscience & therapeutics,
Xingliang Dai, and Yunfei Wang, and Xuchen Dong, and Minfeng Sheng, and Haiyang Wang, and Jia Shi, and Yujing Sheng, and Liang Liu, and Qianqian Jiang, and Yanming Chen, and Bingshan Wu, and Xuejun Yang, and Hongwei Cheng, and Chunsheng Kang, and Jun Dong
December 2016, Journal of physiology and biochemistry,
Xingliang Dai, and Yunfei Wang, and Xuchen Dong, and Minfeng Sheng, and Haiyang Wang, and Jia Shi, and Yujing Sheng, and Liang Liu, and Qianqian Jiang, and Yanming Chen, and Bingshan Wu, and Xuejun Yang, and Hongwei Cheng, and Chunsheng Kang, and Jun Dong
March 2024, JCI insight,
Xingliang Dai, and Yunfei Wang, and Xuchen Dong, and Minfeng Sheng, and Haiyang Wang, and Jia Shi, and Yujing Sheng, and Liang Liu, and Qianqian Jiang, and Yanming Chen, and Bingshan Wu, and Xuejun Yang, and Hongwei Cheng, and Chunsheng Kang, and Jun Dong
February 2017, Oncogene,
Xingliang Dai, and Yunfei Wang, and Xuchen Dong, and Minfeng Sheng, and Haiyang Wang, and Jia Shi, and Yujing Sheng, and Liang Liu, and Qianqian Jiang, and Yanming Chen, and Bingshan Wu, and Xuejun Yang, and Hongwei Cheng, and Chunsheng Kang, and Jun Dong
May 2013, International journal of oncology,
Xingliang Dai, and Yunfei Wang, and Xuchen Dong, and Minfeng Sheng, and Haiyang Wang, and Jia Shi, and Yujing Sheng, and Liang Liu, and Qianqian Jiang, and Yanming Chen, and Bingshan Wu, and Xuejun Yang, and Hongwei Cheng, and Chunsheng Kang, and Jun Dong
October 2019, European review for medical and pharmacological sciences,
Xingliang Dai, and Yunfei Wang, and Xuchen Dong, and Minfeng Sheng, and Haiyang Wang, and Jia Shi, and Yujing Sheng, and Liang Liu, and Qianqian Jiang, and Yanming Chen, and Bingshan Wu, and Xuejun Yang, and Hongwei Cheng, and Chunsheng Kang, and Jun Dong
January 2021, Cytokine,
Xingliang Dai, and Yunfei Wang, and Xuchen Dong, and Minfeng Sheng, and Haiyang Wang, and Jia Shi, and Yujing Sheng, and Liang Liu, and Qianqian Jiang, and Yanming Chen, and Bingshan Wu, and Xuejun Yang, and Hongwei Cheng, and Chunsheng Kang, and Jun Dong
January 2021, Frontiers in cell and developmental biology,
Copied contents to your clipboard!